Futura Medical Share Discussion Threads

[lbo] 03/5/2023 10:25

The multi-ID ramper also claimed onADVFN it was 'FACTS' Med3000/Eroxon was 'clinically proven'But now Futura has admitted on the HCP website none of the Eroxon studies were adequately placebo controlled!Medical device claims that breach CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices'Because the trial was not placebo-controlled''had not provided adequate evidence to support the claim 'clinically proven' ˜concluded that the claim had not been substantiated and was misleading'https://www.asa.org.uk/rulings/actegy-ltd-g20-1053158-actegy-ltd.htmlAssessmentUpheldThe ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation.CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims.There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacyhttps://pocketdentistry.com/asa-ruling-on-orthoaccel-technologies-inc-ta-acceledent/Because the trial was not placebo-controlled, we considered AcceleDent had not provided adequate evidence to support the claim AcceleDent, is also clinically proven to reduce the pain and discomfort associated with braces and aligners by up to 71%. We concluded that the claim had not been substantiated and was misleading.On that point the claim breached CAP Code (Edition 12) rules 3.1 (Misleading advertising), 3.7 (Substantiation) and 12.1 Medicines, medical devices, health-related products and beauty products.https://www.asa.org.uk/rulings/actegy-ltd-g20-1053158-actegy-ltd.htmlAssessmentUpheldThe ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation.CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims.There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy

[lbo] 03/5/2023 10:21

petroc 1 May '23 - 16:08 - 18519 of 18523'Boots are a different matter entirely'The Multi-ID ramper is just proven wrong over and over again!! ROFLMAOhttps://polaris.brighterir.com/public/futura_medical/news/rns/story/xp9z11w/exporthttps://www.boots-uk.com/newsroom/news/boots-launches-brand-new-online-marketplace/https://www.boots-uk.com/suppliers/become-a-boots-marketplace-seller/Launching in Spring 2023, Boots Marketplace will allow brands of any size to seamlessly list their products on boots.comhttps://www.rns-pdf.londonstockexchange.com/rns/3928V_1-2023-4-4.pdfProduct revenue represents net invoice less estimated volume discounts, which are considered to be variable consideration and include significant estimates. Other variable considerations such as milestone payments and royalties are not recognised in full until it is highly probable that a significant reversal in the amount of cumulative revenue recognised will not occur. In management's opinion, that will be when the Groups customer confirms that the milestone has been met or that a royalty is duehttps://futuramedical.com/media/2187/admission_doc.pdfa agreed percentage of the net sales value (after transport costs, sales tax, credit notes for returns and defective products and any settlement, retrospective, volume and promotional discounts) charged by LRC or any sub-licensee in relation to the Product.The royalty and the royalty advance may be reduced by such amount (if any) as is agreed or determined by an expert to be fair and reasonable if: (i) any patent application does not proceed to grant or any patent rights are determined to be unenforceable or are revoked or lapse; or (ii) an event occurs which in LRC reasonable opinion adversely affects the commercial viability of the licence agreement or the margins on sales of the Product; or (iii) a competing product is offered

[lbo] 03/5/2023 10:19

Yet again the multi-ID ramper cannot substantiate any of his false and misleading claims with any non deficient evidence! Just like all the multi-ID ramper claimed 'FACTS'. Just more and more proven lies. And here Futura are over a year later and still no enforceable patent. Ironic the proven liar said 'soon' and Joe said everything with Futura is measured in 'decades'So where is the enforceable patent over a year later?petroc - 21 Jan 2022 - 18:03:42 - 10541 of 10710What is not to love Eroxon /MED3000 - HERE ARE THE FACTS- Patent application in progress using patent lawyers - COMING SOONSo basically any company or lubricant manufacturer like Reckitt can launch their own placebo arousal Erectile gels made of alcohol, water, glycol and carbomer! Even Pfizer or Boots could launch a similar arousal gel under its already established Viagra type brands and claims like Futura its placebo arousal gel is 'clinically proven' in deficient tests to have an effect in Psychological ED!ROFLMAOhttps://www.jdsupra.com/legalnews/lilly-s-cialis-patent-claims-extending-6978893/'Lillys CIALIS patent claims extending to physiologically acceptable salt found invalid for overbreadth and insufficiency'https://indigo.bluematrix.com/indigo/Viewer.action?info=U7Z%2F%2BSxWYbPQB8QtqH%2Bh5KgushbvU5dK'TPR100 gave similar results to the gold standard, Voltarol 2% gel'https://www.dovepress.com/testing-topical-products-specifically-to-reduce-inflammatory-pain-from-peer-reviewed-fulltext-article-JPRVoltarol Emugel vehicle gel is made of the same ˜evaporative cooling' ingredients as in Eroxon. Its even off patent same as Dermasys is!carbomer,isopropyl alcohol,propylene glycol,waterhttps://www.perrigo.com/press-release/perrigo-announces-store-brand-equivalent-voltarenr-arthritis-pain-available-us-majorPerrigo Company plc today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now available in the U.S. nationwidehttps://www.gskhealthpartner.com/content/dam/cf-consumer-healthcare/health-professionals/en_IN/pdf/article-1.pdfThe cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moisturizing properties and fragrance.https://www.edisoninvestmentresearch.com/?ACT=18&ID=10479A key element of Futura Medicals strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect

[lbo] 03/5/2023 09:55

Erectile Dysfunction Drugs Shown to Prevent Major Adverse Cardiovascular Events





PDE5 inhibitors lowered risk of CHF, MI, overall mortality in men with ED and CVD



Boots sales boosted by new own-brand Viagra rival
Treatment is the pharmacy's first erectile dysfunction product that is sold without a prescription

[lbo] 03/5/2023 08:48

Same happened also with all Futura’s other failed products. All initially sold out! Even Futura have admitted in the results they will need to ˜work hard’ to try turn it ˜into a long term, profitable and trusted brand’


superg1 - 27 Jan 2014 - 07:23:44 - 9314 of 11722

Well it reads well re the launch in stores throughout the US and online. It will obvious who they have launched with once it's for sale, but I would imagine that will mean another rns when it launches anyway stating who it is.

Interesting that Ansell will be promoting it individually and as a package.

Green Web sold out in quick time so it will be interesting to see how well it goes on a full launch.

superg1 - 21 Jan 2014 - 19:22:44 - 9300 of 11722
A post on iii today.

Some will know what it is all about

After contacting Green web the Amazon the retailers of PET500 I have been told that they "bought every available unit offered by the suppliers". They are keen to get more stock. I made no pretence as to my identity although avoided mentioning I was a FUM investor in my enquiries and simply asked why it was no longer being offered and why the online reviews were allocated. I was asked " Do you work for Ansell? We are extremely interested in continuing to carry the EPIC spray product."

I believe the major U.S. retailers Amazon and others are competing to offer the product for the follow-on 'major' launch. I always try to manage my own expectations and therefore had assigned EPIC as a useful peripheral product in terms of driving revenues. I think there are signs that EPIC could turn out to be a more than 'useful' revenue generator for FUM.


Looks like punters are desperate for the product, one on ebay apparently sold for $419 (from iii)




loobrush - 13 May 2014 - 14:01:03 - 9696 of 11722

EPIC spray out of stock at AMAZON-is it all sold out?

Weildy2 - 14 May 2014 - 17:47:44 - 9709 of 11722

OK Guys, here is my take on the FUM AGM yesterday.

PET sales launched at 850 Walmart stores three weeks ago and should be available on line by the end of this week. Although it is far too soon to report sales figures, it has been selling in larger quantities than anticipated.

Ansell are negotiating with other retailers. Will be sold through Walgreen (the US equivalent of Boots Chemist) which tOpgrader estimates to be approximately 870 stores.

[lbo] 03/5/2023 08:44

Flexiseq another class 2 medical device drug free gel that also is rubbed in also initially sold out but then ended up on the verge of bankruptcy!



2013


Chemist shops sold out of new treatment three times since product came out in June
flying off pharmacy shelves at the rate of 15,000 tubes a week



Flexiseq, an innovative topical pain product that has sales of more than 3 million units since its U.K. launch last year.



In 2017, PBB was on the verge of bankruptcy, because it could not pay interest on the loan of 15 million pounds, taken in 2015 by the Canadian Knight Therapeutics.

[freddievas] 03/5/2023 08:41

Tried two airport Boots outlets, both sold out.

[broomrigg] 03/5/2023 08:01

I love a blue day because I'm a shareholder Glavey, that's my excuse. What's yours? Hanging about in the chatroom of a stock in which you have zero invested, posting often at 2am......what a sad useless life you must lead. Reminds me of broke nutjob LBO.

Looking forward to more blue, whenever that may be :-)

[glavey] 03/5/2023 07:04

"Love a BLUE start..."

Enjoy it whilst you can Broomrigg, for you'll surely learn that share prices change both positively and negatively from time to time. Oh, and if you hadn't noticed I wasn't addressing you in person previously so there was no need for your childish sally, or was it just that you felt the urge to demonstrate that you had nothing more intelligent to offer? In which case please do carry on.

[lbo] 02/5/2023 19:58

How old are the Dermasys and Eroxon trademark names now?! Dermasys on its own dates back to 2002 and oj its own doesn’t even have a patent anymore!



‘The DermaSys(R) technology was originally developed by Futura for use in the Company's topical treatment for erectile dysfunction, MED2002’



Eroxon

the trademark (UK No 2,320,890 (Class 5)) for which the Company has applied, for the product also known as MED 2000




Like the brokers admitting in their previous research that they are assuming the original Med2002/2005 patents which expire in 2025 in EU and USA in 2028 will provide some protection to Med3000 until then. Thats a big assumption as the original MED patent was an umbrella patent covering Dermasys with GTN. Med3000 now is just Dermasys on its own and dates back to 2002 and is now just a medical device delivering only a cooling sensation via ‘evaporative cooling’

[lbo] 02/5/2023 19:54

Just like all the multi-ID ramper claimed ˜FACTS’. Just more and more proven lies. And here Futura are over a year later and still no enforceable patent. Ironic the proven liar said ‘soon’ and Joe said everything with Futura is measured in ‘decades’

So where is the enforceable patent over a year later?


petroc - 21 Jan 2022 - 18:03:42 - 10541 of 10710
What is not to love Eroxon /MED3000 - HERE ARE THE FACTS

- Patent application in progress using patent lawyers - COMING SOON


So basically any company or lubricant manufacturer like Reckitt can launch their own placebo arousal Erectile gels made of alcohol, water, glycol and carbomer! Even Pfizer or Boots could launch a similar arousal gel under its already established Viagra type brands and claims like Futura its placebo arousal gel is ˜clinically proven’ in deficient tests to have an effect in Psychological ED!

ROFLMAO



‘Lillys CIALIS patent claims extending to physiologically acceptable salt found invalid for overbreadth and insufficiency’



‘TPR100 gave similar results to the gold standard, Voltarol 2% gel’



Voltarol Emugel vehicle gel is made of the same ‘evaporative cooling’ ingredients as in Eroxon. Its even off patent same as Dermasys is!

carbomer,
isopropyl alcohol,
propylene glycol,
water



Perrigo Company plc today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now available in the U.S. nationwide



The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results. Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moisturizing properties and fragrance.



A key element of Futura Medicals strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect

[petroc] 02/5/2023 19:48

What's happened to your up-voter, LiarBO? Did you panic after my heads-up to the mods? Hahahaha!

[lbo] 02/5/2023 19:40

FTC And NAD Remind Industry Of Their Authority Over All Health Product Advertisinghttps://www.mondaq.com/unitedstates/life-sciences-biotechnology--nanotechnology/1290068/ftc-and-nad-remind-industry-of-their-authority-over-all-health-product-advertising-including-rxFTC shares jurisdiction with FDA over the marketing of dietary supplements, foods, drugs, medical devices, and other health-related products. Pursuant to a Memorandum of Understanding between the two agencies, FDA has primary responsibility over claims that appear on labeling, while FTC has primary responsibility for claims made in advertising. Both agencies require health-related marketing to be truthful and substantiated. Unlike FDA, however, FTC does not distinguish between categories of health-related products or claims in evaluating advertising claims. Rather, according to FTC, "the FTC's approach to the advertising of health-related products is the same regardless of whether, under FDA law, the product is considered a food, a supplement[,] or a drug."3 Moreover, FTC has emphasized that the Memorandum of Understanding does not "limit the FTC's jurisdiction or prohibit the agency from taking action against deceptive labeling claims or obtaining orders that address all forms of marketing, including claims that appear in labeling."4Ensure Clear and Conspicuous Disclosureâ€â€?Where disclosure of qualifying information is necessary, FTC requires such disclosure to be presented clearly and conspicuously, so "it is difficult to miss (i.e., noticeable) and easily understandable by ordinary consumersMonitor the Quality of the Evidenceâ€â€?Additionally, FTC discusses that it will also examine the internal validity of each piece of evidence provided to support a health claim. FTC advises marketers to ensure the research on which they rely complies with the following basic principles:The human clinical trial should have both a treatment group and a control group;The study should be randomized;The study should be double blinded;https://www.fdli.org/2023/02/ftc-and-nad-remind-industry-of-their-authority-over-all-health-product-advertising-including-rx/FTC and NAD Remind Industry of Their Authority Over All Health Product Advertising

[broomrigg] 02/5/2023 19:25

Looking forward to FDA approval and news of Eroxon roll-out in lots more countries for 2 reasons.....1. I have money invested2. I love laughing at the clueless broke goon LBO.Happy days :-)

[lbo] 02/5/2023 19:17

And lets not forget what mike has previously said about Mr Barder ‘waffling̵7; and he doesn’t ‘give any credence to virtually everything he says’. But now mike is desperate to get out at the expense or others while all is looking rosy’ so he will say anything to pump the ‘placebo gel frenzy’!

mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141

Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he says

mikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141

Company is massively over valued if you go by 'concrete' results !

mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141

I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.
I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the shares
Unfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !

mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591

"A couple of decent deals and will be back off to the races."
Do you have any idea of how long shareholders have been using these words

mikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591

As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.
All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!

mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713

why should it be any different this time when you've still got the same useless lot running the show

mikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641

I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-life
And where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remuneration
I just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a